Last reviewed · How we verify
NCT03903588
The Heidelberg Engineering SPECTRALIS Macular Precision and Agreement Study
trial testing Optical Coherence Tomography in Retinal Layer Separation in 86 participants. Completed in 12 September 2019.
12 September 2019
Quick facts
| Lead sponsor | Heidelberg Engineering GmbH |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 86 |
| Start date | 22 March 2019 |
| Primary completion | 12 September 2019 |
| Estimated completion | 12 September 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Optical Coherence Tomography
Conditions studied
- Retinal Layer Separation — all drugs for Retinal Layer Separation →
Sponsor
Heidelberg Engineering GmbH
Who can join
22 and older, any sex, with Retinal Layer Separation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective clinical study that will be conducted at one clinical site located in the United States to assess two grids.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03903588
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Optical Coherence Tomography
Trials testing the same drug.
- NCT06906562 — A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metasta · Phase 2 · recruiting
- NCT07060196 — The Impact of Artificial Lighting on the Visual Capacity of Patients With Age-Related Macular Degeneration · not yet recruiting
- NCT07350304 — Comparison of Two OCT Device RNFL and GCIPL Measurements in Mild, Moderate, and Severe Glaucoma · completed
- NCT06419114 — Exploration of Optical Coherence Tomography-Guided Transbronchial Biopsy in Peripheral Pulmonary Lesions · recruiting
- NCT05859334 — Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment · Phase 2 · recruiting
Other Heidelberg Engineering GmbH trials
Trials by the same sponsor.
- NCT07338461 — High Resolution Imaging OCT Study · NA · not yet recruiting
- NCT06397976 — The Heidelberg Engineering ANTERION Software Comparison Precision and Agreement Study · terminated
- NCT05051813 — The Heidelberg Engineering ANTERION Corneal Epithelium Thickness Precision and Agreement Study · completed
- NCT04961398 — Evaluation of Heidelberg Engineering SPECTRALIS OCT Signal to Noise Ratio Effect on Parameter Measurements · completed
- NCT04661124 — Evaluation of the Heidelberg Engineering SPECTRALIS With Flex Module for In-vivo Imaging in the Supine Position · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03903588 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Heidelberg Engineering GmbH
- Last refreshed: 22 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03903588.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing